- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Matthew Cooperberg addresses the controversial topic of reclassifying Grade Group 1 prostate cancer. He argues that what is currently labeled as low-grade prostate cancer is essentially a normal feature of male aging and questions whether it should be considered cancer at all. Dr. Cooperberg high...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Adam Kibel presents counterarguments to reclassifying Grade Group 1 prostate cancer as non-cancer. He acknowledges the low risk of harm in patients who undergo radical prostatectomy for Grade Group 1 cancer but emphasizes that some patients with initial Grade Group 1 biopsies eventually progress...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Laura Esserman discusses the importance of reclassifying certain cancers, focusing on the impact of terminology and the need for more precise classification methods. She highlights the problem of overdiagnosis in cancer screening, particularly for indolent cancers, and emphasizes the need for obj...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Gladell Paner discusses the feasibility of reclassifying Grade Group 1 (GG1) prostate cancer from a pathological perspective. He acknowledges the debate between histologic features of cancer and the lack of clinical symptoms or metastasis in GG1 cases. Dr. Paner concludes that accepting a borderl...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Theo van der Kwast argues against reclassifying Grade Group 1 prostate cancer, emphasizing the pathological definition of adenocarcinoma. He highlights the infiltrative and locally aggressive nature of these tumors, noting their potential for perineural invasion and extraprostatic extension. He a...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Jeff Simko provides analogies from other cancer types to inform the debate on reclassifying Grade Group 1 prostate cancer. He presents the example of tubular breast cancer, which histologically resembles Gleason 3+3 prostate cancer but has a 100% survival rate despite being invasive. Biographies:...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Lawrence True addresses the sampling issue in prostate cancer diagnosis, focusing specifically on biopsy results. Biographies: Lawrence True, MD, Pathologist, University of Washington, Seattle, WA Related Content: Pathology Perspective: CG1 is Still Cancer "Presentation" - Theodorus van der Kwast...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Alastair Lamb hosts two speakers who explore the nuances of breast cancer diagnosis and treatment in relation to the broader debate about cancer classification. Biographies: Alastair Lamb, FRCS (Urol), PhD, MBChB, MA, Associate Professor, Nuffield Department of Surgical Sciences, Oxford Universit...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Alastair Lamb discusses the molecular basis of prostate cancer behavior using spatial transcriptomics. He demonstrates how this technique creates high-resolution clonal maps of prostates, revealing transcriptomic and genomic information at near-cellular levels while preserving tissue structure. B...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Daniel Lin discusses the implications of potentially reclassifying Grade Group 1 prostate cancer as non-cancer in the context of active surveillance. Dr. Lin highlights the current understanding of grade reclassification as a primary driver in active surveillance decisions, noting that upgrading...
|
